Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77054


Purpose:

To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.


Criteria:

Inclusion Criteria Patients must have: - HIV-1 seropositivity. - Absolute number of T4 cells 100-300 cells/mm3. - Given informed consent. - Zidovudine (AZT) therapy for 6 months prior to study entry. - At least one of the listed HIV-related clinical symptoms or opportunistic infections: - weight loss > 10 percent, unexplained diarrhea, unexplained intermittent fever, oral candidiasis > 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Evidence of AIDS. - Intercurrent acute medical disorder. Concurrent Medication: Excluded: - Chemotherapy for Kaposi's sarcoma (KS). - Aspirin. - Non-steroidal anti-inflammatory drugs. Patients with the following are excluded: - Inability to return for treatment and evaluation for 12 months. - Intercurrent acute medical disorder. - Evidence of AIDS. - Receiving chemotherapy for Kaposi's sarcoma (KS). - Unwilling or unable to give informed consent. Required: - Zidovudine (AZT). Required at least 6 months prior to study entry: - Zidovudine (AZT). Active drug abuse.


Study is Available At:


Original ID:

073A


NCT ID:

NCT00002269


Secondary ID:

AMP-700


Study Acronym:


Brief Title:

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen


Official Title:

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen


Overall Status:

Completed


Study Phase:

N/A


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

NIH AIDS Clinical Trials Information Service


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Masking: Double-Blind, Primary Purpose: Treatmen


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

0


Enrollment Type:


Study Dates

Verification Date:August 1991
Last Changed Date:June 23, 2005
First Received Date:November 2, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:Ampligen
Intervention Type:Drug
Name:Zidovudine

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:HEM Research

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.